Gokhale, P., Caballero, J., Li, N., Zapata, L. A. V. (2026). Cost-effectiveness of amivantamab plus lazertinib versus osimertinib plus chemotherapy for first-line treatment of EGFR ‐mutated advanced non–small cell lung cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8621